长期氯胺酮输注致COVID-19相关ARDS患者胆汁淤积性肝损伤
该研究为2020年3月至2021年8月前瞻性观察队列的事后分析,纳入243例COVID-19相关ARDS危重患者,其中170例(70%)接受氯胺酮输注,速率1.4 [0.9-2.0] mg/kg/h,持续9 [4-18]天。采用时变多变量校正累积加权暴露混合效应模型分析,发现氯胺酮输注时长与剂量均与总胆红素升高正相关(p < 0.0001),而长期输注丙泊酚和舒芬太尼即使高剂量也与胆红素升高无关(p = 0.421,p = 0.258)。接受氯胺酮者ICU期间发生胆汁淤积性肝损伤的多变量校正竞争风险比为3.2 [95%CI 1.3-7.8](p = 0.01)。作者认为应尽可能避免对机械通气COVID-19患者长期使用大剂量氯胺酮进行镇痛镇静。
要点
- 243例COVID-19相关ARDS患者中170例(70%)接受氯胺酮输注,速率1.4 [0.9-2.0] mg/kg/h,持续9 [4-18]天。
- 混合效应模型显示氯胺酮输注时长与剂量均与总胆红素升高正相关(p < 0.0001)。
- 长期输注丙泊酚和舒芬太尼即使高剂量也与胆红素升高无关(p = 0.421,p = 0.258)。
- 接受氯胺酮者ICU期间发生胆汁淤积性肝损伤的多变量校正竞争风险比为3.2 [95%CI 1.3-7.8](p = 0.01)。
- 作者建议对机械通气COVID-19患者长期镇痛镇静时尽可能避免大剂量氯胺酮。
适用人群与场景
- 2020年3月至2021年8月收治的COVID-19相关ARDS危重患者,共243例纳入分析。
处置流程与药物剂量
- 170例(70%)患者接受氯胺酮输注,速率1.4 [0.9-2.0] mg/kg/h,持续9 [4-18]天。
研究设计与关键结果
- 研究类型为前瞻性观察队列的事后分析,纳入243例COVID-19相关ARDS患者,其中170例(70%)接受氯胺酮输注。
- 采用时变多变量校正累积加权暴露混合效应模型,发现氯胺酮输注时长与剂量均与总胆红素升高正相关(p < 0.0001)。
- 长期输注丙泊酚和舒芬太尼即使高剂量也与胆红素升高无关(p = 0.421,p = 0.258)。
- 接受氯胺酮输注者ICU期间发生胆汁淤积性肝损伤的多变量校正竞争风险比为3.2 [95%CI 1.3-7.8](p = 0.01)。
证据类型、等级与局限
- 证据类型:前瞻性观察队列的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对机械通气COVID-19患者进行长期镇痛镇静时,应尽可能避免使用大剂量氯胺酮。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A higher-than-usual resistance to standard sedation regimens in COVID-19 patients suffering from acute respiratory distress syndrome (ARDS) has led to the frequent use of the second-line anaesthetic agent ketamine. Simultaneously, an increased incidence of cholangiopathies in mechanically ventilated patients receiving prolonged infusion of high-dose ketamine has been noted. Therefore, the objective of this study was to investigate a potential dose-response relationship between ketamine and bilirubin levels.
METHODS: Post hoc analysis of a prospective observational cohort of patients suffering from COVID-19-associated ARDS between March 2020 and August 2021. A time-varying, multivariable adjusted, cumulative weighted exposure mixed-effects model was employed to analyse the exposure-effect relationship between ketamine infusion and total bilirubin levels.
RESULTS: Two-hundred forty-three critically ill patients were included into the analysis. Ketamine was infused to 170 (70%) patients at a rate of 1.4 [0.9-2.0] mg/kg/h for 9 [4-18] days. The mixed-effects model revealed a positively correlated infusion duration-effect as well as dose-effect relationship between ketamine infusion and rising bilirubin levels (p < 0.0001). In comparison, long-term infusion of propofol and sufentanil, even at high doses, was not associated with increasing bilirubin levels (p = 0.421, p = 0.258). Patients having received ketamine infusion had a multivariable adjusted competing risk hazard of developing a cholestatic liver injury during their ICU stay of 3.2 [95% confidence interval, 1.3-7.8] (p = 0.01).
CONCLUSIONS: A causally plausible, dose-effect relationship between long-term infusion of ketamine and rising total bilirubin levels, as well as an augmented, ketamine-associated, hazard of cholestatic liver injury in critically ill COVID-19 patients could be shown. High-dose ketamine should be refrained from whenever possible for the long-term analgosedation of mechanically ventilated COVID-19 patients.
参考来源
- Wendel-Garcia PD, Erlebach R, Hofmaenner DA, et al. Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome. Crit Care. 2022. PMID: 35606831. doi:10.1186/s13054-022-04019-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。